GlassScriptPhysician profile
Carol C Lekan
NPI 1265426571
$5,986.93
in general payments reported to CMS, 2019-2025
25 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $167 · 2021: $477 · 2022: $1,395 · 2023: $1,397 · 2024: $1,388 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.14 |
| Education | $102.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,692.19 | 2019-2024 | |
| Genzyme Corporation | $536.53 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $409.58 | 2022-2024 | Sotyktu |
| Ucb, INC. | $408.28 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $405.84 | 2019-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $330.70 | 2019-2024 | Ilumya, Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $286.43 | 2023-2025 | Zoryve |
| Almirall LLC | $250.37 | 2019-2023 | Seysara, Klisyri |
| Novartis Pharmaceuticals Corporation | $245.98 | 2019 | |
| Janssen Biotech, INC. | $242.84 | 2022-2025 | Tremfya |
| Pfizer INC. | $219.60 | 2021-2024 | |
| Leo Pharma INC. | $170.66 | 2019-2023 | Adbry |
| Incyte Corporation | $148.38 | 2021-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.23 | 2019-2020 | |
| Lilly USA, LLC | $119.18 | 2021-2024 | Olumiant |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $110.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $80.12 | 2019-2024 | Libtayo |
| Dermavant Sciences, INC. | $46.12 | 2022-2023 | Vtama |
| Galderma Laboratories, L.P. | $34.67 | 2023 | Oracea, Aklief |
| Dermira, INC. | $22.58 | 2019 | |
| Prugen, INC. Pharmaceuticals | $18.66 | 2019 | |
| Genentech USA, INC. | $18.35 | 2023 | Xolair |
| Journey Medical Corporation | $16.52 | 2022 | |
| Mayne Pharma Commercial LLC | $16.06 | 2019 | |
| Merck Sharp & Dohme LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Lekan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.